This study has been designed to elucidate mechanisms by which neonatal chronic lung disease occurs and to test the capacity and safety of inhaled glucocorticoid to prevent the process of chronic lung disease and its accompanying effects on growth and development. This will be accomplished through a randomized, placebo controlled clinical trial of inhaled corticosteroid, beclomethasone dipropionate, in infants less than 1251 gm birth weight and less than 33 weeks gestation who, at 3 to 14 days of age, continue to have respiratory difficulties.
Showing the most recent 10 out of 412 publications